{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T16:53:47Z","timestamp":1780505627707,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000046","name":"Gouvernement du Canada | National Research Council Canada","doi-asserted-by":"publisher","award":["CGT-101"],"award-info":[{"award-number":["CGT-101"]}],"id":[{"id":"10.13039\/501100000046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201910MFE-430323-FPP-CAAA-267763"],"award-info":[{"award-number":["201910MFE-430323-FPP-CAAA-267763"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["RT-2020-0381"],"award-info":[{"award-number":["RT-2020-0381"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41434-025-00524-x","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T20:00:57Z","timestamp":1743019257000},"page":"197-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimization of adeno-associated viral (AAV) gene therapies vectors for balancing efficacy, longevity and safety for clinical application"],"prefix":"10.1038","volume":"32","author":[{"given":"Neel","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-2111","authenticated-orcid":false,"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder S.","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasha","family":"Nassoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Coulombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gingras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaka","family":"Mullick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Drouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sasseville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Latawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnaraj","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8848-5529","authenticated-orcid":false,"given":"Emily M.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fudan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J. D.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-1419","authenticated-orcid":false,"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"524_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/hae.14984","volume":"30","author":"R Kaczmarek","year":"2024","unstructured":"Kaczmarek R, Miesbach W, Ozelo MC, Chowdary P. Current and emerging gene therapies for haemophilia A and B. Haemophilia. 2024;30:12\u201320.","journal-title":"Haemophilia"},{"key":"524_CR2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1182\/blood-2023-186891","volume":"142","author":"UM Reiss","year":"2023","unstructured":"Reiss UM, Davidoff AM, Tuddenham EGD, Chowdary P, McIntosh JH, Riddell A, et al. Stable therapeutic transgenic FIX levels for more than 10 years in subjects with severe hemophilia B who received scAAV2\/8-LP1-Hfixco adeno-associated virus gene therapy. Blood. 2023;142:1056\u20131056.","journal-title":"Blood"},{"key":"524_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JEJ, et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13:419\u201322.","journal-title":"Nat Med"},{"key":"524_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Arruda VR, Pierce GF, Glader B, Ragni M, Rasko J, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342\u20137.","journal-title":"Nat Med"},{"key":"524_CR5","doi-asserted-by":"publisher","first-page":"e173510","DOI":"10.1172\/JCI173510","volume":"134","author":"SM Salabarria","year":"2024","unstructured":"Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D\u2019Souza P, et al. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Investig. 2024;134:e173510.","journal-title":"J Clin Investig"},{"key":"524_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","volume":"28","author":"JF Wright","year":"2020","unstructured":"Wright JF. Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare? Mol Ther. 2020;28:701\u20133.","journal-title":"Mol Ther"},{"key":"524_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood.2019004625","volume":"137","author":"BA Konkle","year":"2021","unstructured":"Konkle BA, Walsh CE, Escobar MA, Josephson NC, Young G, von Drygalski A, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021;137:763\u201374.","journal-title":"Blood"},{"key":"524_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ymthe.2019.11.014","volume":"28","author":"ZQ Xiang","year":"2019","unstructured":"Xiang ZQ, Kurupati RK, Li Y, Kuranda K, Zhou X, Mingozzi F, et al. The effect of CpG sequences on capsid-specific CD8+ T cell responses to AAV vector gene transfer. Mol Ther. 2019;28:771\u201383.","journal-title":"Mol Ther"},{"key":"524_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.672449","volume":"12","author":"TB Bertolini","year":"2021","unstructured":"Bertolini TB, Shirley JL, Zolotukhin I, Li X, Kaisho T, Xiao W, et al. Effect of CpG depletion of vector genome on CD8+ T cell responses in AAV gene therapy. Front Immunol. 2021;12:1\u201311.","journal-title":"Front Immunol"},{"key":"524_CR10","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.3389\/fimmu.2021.675897","volume":"12","author":"BA Hamilton","year":"2021","unstructured":"Hamilton BA, Wright JF. Challenges posed by immune responses to AAV vectors: addressing root causes. Front Immunol. 2021;12:1654.","journal-title":"Front Immunol"},{"key":"524_CR11","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1172\/JCI68205","volume":"123","author":"SM Faust","year":"2013","unstructured":"Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Investig. 2013;123:2994\u20133001.","journal-title":"J Clin Investig"},{"key":"524_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1089\/hum.2023.075","volume":"34","author":"N Mehta","year":"2023","unstructured":"Mehta N, Gilbert R, Chahal PS, Moreno MJ, Nassoury N, Coulombe N, et al. Preclinical Development and characterization of novel adeno-associated viral vectors for the treatment of lipoprotein lipase deficiency. Hum Gene Ther. 2023;34:927\u201346.","journal-title":"Hum Gene Ther"},{"key":"524_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MOL.0000000000000297","volume":"27","author":"G Olivecrona","year":"2016","unstructured":"Olivecrona G. Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipido. 272016;233\u201341.","journal-title":"Curr Opin Lipido"},{"key":"524_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1152\/ajpendo.90920.2008","volume":"297","author":"H Wang","year":"2009","unstructured":"Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297:271\u201388.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"524_CR15","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1194\/jlr.R200015-JLR200","volume":"43","author":"M Merkel","year":"2002","unstructured":"Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 2002;43:1997\u20132006.","journal-title":"J Lipid Res"},{"key":"524_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0022-2275(20)37569-6","volume":"37","author":"IJ Goldberg","year":"1996","unstructured":"Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37:693\u2013707.","journal-title":"J Lipid Res"},{"key":"524_CR17","first-page":"d388","volume":"6","author":"IraJ Goldberg","year":"2001","unstructured":"Goldberg IraJ. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci. 2001;6:d388.","journal-title":"Front Biosci"},{"key":"524_CR18","first-page":"249","volume":"37","author":"A Chait","year":"1992","unstructured":"Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med. 1992;37:249\u201373.","journal-title":"Adv Intern Med"},{"key":"524_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/MOL.0000000000000676","volume":"31","author":"D Basu","year":"2020","unstructured":"Basu D, Goldberg IJ. Regulation of lipoprotein lipase-mediated lipolysis of triglycerides. Curr Opin Lipido. 2020;31:154\u201360.","journal-title":"Curr Opin Lipido"},{"key":"524_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fendo.2020.593931","volume":"11","author":"RB Goldberg","year":"2020","unstructured":"Goldberg RB, Chait A. A comprehensive update on the chylomicronemia syndrome. Front Endocrinol. 2020;11:830.","journal-title":"Front Endocrinol"},{"key":"524_CR21","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1089\/hum.2004.15.906","volume":"15","author":"CJD Ross","year":"2004","unstructured":"Ross CJD, Twisk J, Meulenberg JM, Liu G, Van Den Oever K, Moraal E, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPLS447X beneficial mutation. Hum Gene Ther. 2004;15:906\u201319.","journal-title":"Hum Gene Ther"},{"key":"524_CR22","doi-asserted-by":"publisher","first-page":"12631","DOI":"10.1073\/pnas.95.21.12631","volume":"95","author":"AM Krieg","year":"1998","unstructured":"Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA. 1998;95:12631\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"524_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00418-016-1447-2","volume":"146","author":"A Rosas-Arellano","year":"2016","unstructured":"Rosas-Arellano A, Villalobos-Gonz\u00e1lez JB, Palma-Tirado L, Beltr\u00e1n FA, C\u00e1rabez-Trejo A, Missirlis F, et al. A simple solution for antibody signal enhancement in immunofluorescence and triple immunogold assays. Histochem Cell Biol. 2016;146:421\u201330.","journal-title":"Histochem Cell Biol"},{"key":"524_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/01.ATV.0000219283.10832.43","volume":"26","author":"J Rip","year":"2006","unstructured":"Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJP, et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol. 2006;26:1236\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"524_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/hum.2006.17.487","volume":"17","author":"CJD Ross","year":"2006","unstructured":"Ross CJD, Twisk J, Bakker AC, Miao F, Verbart D, Rip J, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther. 2006;17:487\u201399.","journal-title":"Hum Gene Ther"},{"key":"524_CR26","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1089\/hum.2013.063","volume":"24","author":"JJP Kastelein","year":"2013","unstructured":"Kastelein JJP, Ross CJD, Hayden MR. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the western world. Hum Gene Ther. 2013;24:472\u20138.","journal-title":"Hum Gene Ther"},{"key":"524_CR27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/gt.2012.43","volume":"20","author":"D Gaudet","year":"2013","unstructured":"Gaudet D, M\u00e9thot J, D\u00e9ry S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPL S447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther. 2013;20:361\u20139.","journal-title":"Gene Ther"},{"key":"524_CR28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1089\/hum.2015.158","volume":"27","author":"D Gaudet","year":"2016","unstructured":"Gaudet D, Stroes ES, M\u00e9thot J, Brisson D, Tremblay K, Bernelot Moens SJ, et al. Long-term retrospective analysis of gene therapy with Alipogene Tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis. Hum Gene Ther. 2016;27:916\u201325.","journal-title":"Hum Gene Ther"},{"key":"524_CR29","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1161\/ATVBAHA.108.175620","volume":"28","author":"ES Stroes","year":"2008","unstructured":"Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, et al. Intramuscular administration of AAV1-lipoprotein lipaseS447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008;28:2303\u20134.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"524_CR30","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1210\/jc.2011-3002","volume":"97","author":"AC Carpentier","year":"2012","unstructured":"Carpentier AC, Frisch F, Labbe SM, Gagnon R, De Wal J, Greentree S, et al. Effect of alipogene tiparvovec (aav1-lpls447x) on postprandial chylomicron metabolism in Lipoprotein lipase-deficient patients. J Clin Endocrinol Metab. 2012;97:1635\u201344.","journal-title":"J Clin Endocrinol Metab"},{"key":"524_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","volume":"23","author":"D Gaudet","year":"2012","unstructured":"Gaudet D, M\u00e9thot J, Kastelein J. Gene therapy for lipoprotein lipase deficiency. Curr Opin Lipido. 2012;23:310\u201320.","journal-title":"Curr Opin Lipido"},{"key":"524_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1089\/hum.2018.007","volume":"29","author":"U Kassner","year":"2018","unstructured":"Kassner U, Hollstein T, Grenkowitz T, W\u00fchle-Demuth M, Salewsky B, Demuth I, et al. Gene therapy in lipoprotein lipase deficiency: case report on the first patient treated with alipogene tiparvovec under daily practice conditions. Hum Gene Ther. 2018;29:520\u20137.","journal-title":"Hum Gene Ther"},{"key":"524_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41434-021-00296-0","volume":"29","author":"X Pan","year":"2022","unstructured":"Pan X, Yue Y, Boftsi M, Wasala LP, Tran NT, Zhang K, et al. Rational engineering of a functional CpG-free ITR for AAV gene therapy. Gene Ther. 2022;29:333.","journal-title":"Gene Ther"},{"key":"524_CR34","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30:1364.","journal-title":"Mol Ther"},{"key":"524_CR35","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","volume":"28","author":"JF Wright","year":"2020","unstructured":"Wright JF. Quantification of CpG Motifs in rAAV Genomes: avoiding the toll. Mol Ther. 2020;28:1756\u20138.","journal-title":"Mol Ther"},{"key":"524_CR36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2015855118","volume":"118","author":"MBF Hawash","year":"2021","unstructured":"Hawash MBF, Sanz-Rem\u00f3n J, Grenier JC, Kohn J, Yotova V, Johnson Z, et al. Primate innate immune responses to bacterial and viral pathogens reveals an evolutionary trade-off between strength and specificity. Proc Natl Acad Sci USA. 2021;118: e2015855118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"524_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.7150\/ijms.14152","volume":"13","author":"L Wang","year":"2016","unstructured":"Wang L, Wang Z, Zhang F, Zhu R, Bi J, Wu J, et al. Enhancing transgene expression from recombinant aav8 vectors in different tissues using woodchuck hepatitis virus post-transcriptional regulatory element. Int J Med Sci. 2016;13:286.","journal-title":"Int J Med Sci"},{"key":"524_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtn.2016.12.006","volume":"6","author":"MI Patr\u00edcio","year":"2017","unstructured":"Patr\u00edcio MI, Barnard AR, Orlans HO, McClements ME, MacLaren RE. Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina. Mol Ther Nucleic Acids. 2017;6:198\u2013208.","journal-title":"Mol Ther Nucleic Acids"},{"key":"524_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.gt.3302417","volume":"12","author":"SM Kingsman","year":"2005","unstructured":"Kingsman SM, Mitrophanous K, Olsen JC. Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Ther. 2005;12:3\u20134.","journal-title":"Gene Ther"},{"key":"524_CR40","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/sj.gt.3300964","volume":"6","author":"S Pasquini","year":"1999","unstructured":"Pasquini S, Deng H, Reddy ST, Giles-Davis W, Ertl HCJ. The effect of CpG sequences on the B cell response to a viral glycoprotein encoded by a plasmid vector. Gene Ther. 1999;6:1448\u201355.","journal-title":"Gene Ther"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00524-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T09:12:31Z","timestamp":1748250751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00524-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00524-x","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NM, ReG., PSC, MJM, NC, AM, CJDR, MRH are inventors on a patent application related to this work filed by the University of British Columbia and the National Research Council Canada (PCT\/CA2024\/050295). MRH currently serves on the public boards of Ionis Pharmaceuticals, Xenon Pharmaceuticals, Aurinia Pharmaceuticals, Abcellera and 89bio. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental procedures were performed with approval of the Biosafety Committees at the University of British Columbia and the National Research Council of Canada. All procedures involving animals were performed with the approval of the Animal Care Committee at the University of British Columbia and the National Research Council of Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}